HC Wainwright Brokers Increase Earnings Estimates for MLYS

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Equities researchers at HC Wainwright increased their FY2025 earnings per share (EPS) estimates for Mineralys Therapeutics in a research note issued to investors on Wednesday, November 12th. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($2.41) per share for the year, up from their previous forecast of ($2.60). HC Wainwright has a “Buy” rating and a $56.00 price target on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Mineralys Therapeutics’ Q4 2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.54) EPS, Q3 2026 earnings at ($0.57) EPS, Q4 2026 earnings at ($0.62) EPS, FY2026 earnings at ($2.25) EPS, FY2027 earnings at ($2.30) EPS, FY2028 earnings at ($0.80) EPS and FY2029 earnings at $1.54 EPS.

A number of other analysts also recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Wednesday, October 8th. Wall Street Zen upgraded Mineralys Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 22nd. Jefferies Financial Group increased their price target on Mineralys Therapeutics from $15.00 to $26.00 and gave the stock a “hold” rating in a report on Wednesday, September 3rd. Wells Fargo & Company raised their price objective on shares of Mineralys Therapeutics from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, The Goldman Sachs Group boosted their target price on shares of Mineralys Therapeutics from $32.00 to $52.00 and gave the company a “buy” rating in a research report on Tuesday, September 9th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $46.67.

Mineralys Therapeutics Stock Down 6.4%

Shares of NASDAQ MLYS opened at $44.29 on Friday. The company has a market capitalization of $3.51 billion, a PE ratio of -15.01 and a beta of 0.40. Mineralys Therapeutics has a twelve month low of $8.24 and a twelve month high of $47.65. The firm has a fifty day simple moving average of $40.05 and a 200 day simple moving average of $23.78.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.14.

Insider Buying and Selling

In related news, Director Daphne Karydas sold 15,000 shares of the company’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $45.99, for a total transaction of $689,850.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Alexander M. Gold sold 12,742 shares of the company’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $46.50, for a total transaction of $592,503.00. The SEC filing for this sale provides additional information. Insiders have sold a total of 416,793 shares of company stock worth $18,669,643 over the last ninety days. Insiders own 25.56% of the company’s stock.

Hedge Funds Weigh In On Mineralys Therapeutics

Several institutional investors have recently modified their holdings of MLYS. Wellington Management Group LLP grew its stake in Mineralys Therapeutics by 578.6% in the 3rd quarter. Wellington Management Group LLP now owns 783,445 shares of the company’s stock valued at $29,708,000 after purchasing an additional 667,997 shares during the period. FORA Capital LLC purchased a new position in Mineralys Therapeutics in the third quarter valued at about $240,000. Invesco Ltd. grew its position in shares of Mineralys Therapeutics by 630.2% during the 3rd quarter. Invesco Ltd. now owns 187,986 shares of the company’s stock valued at $7,128,000 after acquiring an additional 162,243 shares during the period. Sei Investments Co. purchased a new stake in shares of Mineralys Therapeutics during the 3rd quarter worth approximately $374,000. Finally, Atika Capital Management LLC purchased a new position in Mineralys Therapeutics in the third quarter valued at approximately $6,598,000. 84.46% of the stock is owned by institutional investors.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.